Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma

• Tipo: Artigo em Revista Científica Internacional
• Data: 2017

Autores

Dias, F (Autor) Outra; Teixeira, AL (Autor) Outra; Ferreira, M (Autor) Outra; Adem, B (Autor) Outra; Bastos, N (Autor) Outra; Vieira, J (Autor) Outra; Fernandes, M (Autor) Outra; Sequeira, MI (Autor) Outra; Mauricio, J (Autor) Outra; Lobo, F (Autor) Outra; Morais, A (Autor) Outra; Oliveira, J (Autor) Outra; Kok, K (Autor) Outra; Rui Medeiros (Autor) ICBAS

Revista

Título: Oncotarget

Vol. 8

ISSN: 1949-2553

Editora: Impact Journals

Indexação

ISI Web of Knowledge - 36 Citações

Scopus - 39 Citações

Outras Informações

ID Authenticus: P-00N-JDT

DOI: 10.18632/oncotarget.21733

Abstract (EN): Renal cell carcinoma (RCC) represents a challenge for clinicians since the nonexistence of screening and monitoring tests contributes to the fact that one-third of patients are diagnosed with metastatic disease and 20-40% of the remaining patients will also develop metastasis. Modern medicine is now trying to establish circulating biomolecules as the gold standard of biomarkers. Among the molecules that can be released from tumor cells we can find microRNAs. The aim of this study was to evaluate the applicability of cancer-related miR-210, miR-218, miR-221 and miR-1233 as prognostic biomarkers for RCC. Patients with higher levels of miR-210, miR-221 and miR-1233 presented a higher risk of specific death by RCC and a lower cancer-specific survival. The addition of miR-210, miR-221 and miR-1233 plasma levels information improved the capacity to predict death by cancer in 8, 4% when compared to the current variables used by clinicians. We also verified that hypoxia stimulates the release of miR-210 and miR-1233 from HKC-8, RCC-FG2 and 786-O cell lines. These results support the addition of circulating microRNAs as prognostic biomarkers for RCC.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 12